Mutant cytochrome P450 2B6 proteins and uses thereof
View Patent ↗The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy.
1. An isolated nucleic acid encoding
a CYP2B6 protein comprising
(i) the amino acid sequence of FIG. 1 (SEQ ID NO: 1), or
(ii) a variant or fragment of (i), wherein said variant or fragment is at least 90% identical to residues 1-490 of FIG. 1 (SEQ ID NO: 1) and comprises residues 114V, 199M and 477W as shown in FIG. 1 (SEQ ID NO: 1) and said variant or fragment has an affinity for CPA that is at least 4 times greater than the affinity for CPA of the wild-type protein as shown in FIG. 5 (SEQ ID NO: 5), or
a fusion protein comprising the CYP2B6 protein according to (i) or (ii) and a NADPH-cytochrome P450 reductase protein as shown in FIG. 2 /SEQ ID NO: 2, or variant or fragment thereof, wherein said NADPH-cytochrome P450 reductase protein, variant or fragment thereof is at least 90% identical to residues 57-678 of FIG. 2 (SEQ ID NO: 2).
2. A vector comprising the nucleic acid of claim 1 .
3. A host cell comprising the vector of claim 2 .
4. A method of making a protein, comprising culturing a host cell comprising a vector comprising a nucleic acid encoding
a CYP2B6 protein comprising
(i) the amino acid sequence of FIG. 1 (SEQ ID NO: 1), or
(ii) a variant or fragment of (i), wherein said variant or fragment is at least 90% identical to residues 1-490 of FIG. 1 (SEQ ID NO: 1) and comprises residues 114V, 199M and 477W as shown in FIG. 1 (SEQ ID NO: 1) and said variant or fragment has an affinity for CPA that is at least 4 times greater than the affinity for CPA of the wild-type protein as shown in FIG. 5 (SEQ ID NO: 5), or
a fusion protein comprising the CYP2B6 protein according to (i) or (ii) and a NADPH-cytochrome P450 reductase protein as shown in FIG. 2 /SEQ ID NO: 2, or variant or fragment thereof, wherein said NADPH-cytochrome P450 reductase protein, variant or fragment thereof is at least 90% identical to residues 57-678 of FIG. 2 (SEQ ID NO: 2),
in cell culture conditions suitable for expression of said protein or said fusion protein.
5. The isolated nucleic acid according to claim 1 , wherein said NADPH-cytochrome P450 reductase protein, variant or fragment thereof
(i) differs from SEQ ID NO: 2 by less than 20 conservative amino acid substitutions; and/or
(ii) differs from SEQ ID NO: 2 by less than 20 amino acid deletions or additions; or
(iii) comprises amino acids 57-678 of FIG. 2 (SEQ ID NO: 2).
6. The isolated nucleic acid according to claim 1 , wherein said CYP2B6 protein, variant or fragment thereof
(i) differs from SEQ ID NO: 1 by less than 20 conservative amino acid substitutions;
and/or
(ii) differs from SEQ ID NO: 1 by less than 20 amino acid deletions or additions; or
(iii) comprises amino acids 1-490 of FIG. 1 (SEQ ID NO: 1).
7. The isolated nucleic acid according to claim 1 , wherein said CYP2B6 protein, variant or fragment thereof has at least a 7.9 times increase in CPA-40H catalytic efficiency (V MAX /K M ) in comparison to the wild-type protein.
8. The isolated nucleic acid according to claim 1 , wherein the CYP2B6 protein is upstream of the NADPH-cytochrome P450 reductase.
9. The isolated nucleic acid according to claim 1 , wherein the mutant human CYP2B6 protein and the NADPH-cytochrome P450 reductase are separated by a linker.
10. The isolated nucleic acid according to claim 9 , wherein the linker consists of 3 to 30 nucleotide residues.
11. The isolated nucleic acid according to claim 9 , wherein said isolated nucleic acid has the sequence of FIG. 3 (SEQ ID NO: 3).